<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00625521</url>
  </required_header>
  <id_info>
    <org_study_id>ASF1096-201</org_study_id>
    <nct_id>NCT00625521</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions</brief_title>
  <official_title>Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Patients With Newly Developed Discoid Lupus Erythematosus (DLE) Lesions. An International Multi-Centre Clinical Phase 2, Placebo Controlled and Double Blind Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astion Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astion Pharma A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lupus Erythematosus (LE) is an autoimmune disorder that includes a broad spectrum of clinical
      forms. One of these forms, Discoid Lupus Erythematosus (DLE) is a chronic disfiguring disease
      confined to the skin.

      The aim of this pivotal trial is to investigate the efficacy and safety of ASF-1096 cream
      0.5% in the treatment of patients with DLE or SLE presenting newly developed discoid lesions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile, CLASI score, GIA and GPA.</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Discoid Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: ASF 1096 0.5 % cream applied twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cream vehicle for ASF 1096 cream applied twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASF 1096 0.5 % cream applied twice daily</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cream vehicle for ASF 1096 cream applied twice daily</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical diagnosis of either DLE or SLE

          -  Histological results from biopsy confirming the diagnosis (biopsy can be taken at
             screening)

          -  Is prepared to grant authorised persons access to the medical records

          -  Has signed informed consent

        Exclusion Criteria:

          -  Has an active skin disease other than DLE or another progressive or serious disease
             that interferes with the study outcome

          -  Has scarring at the target lesion

          -  Systemic treatment of SLE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Filippa Nyberg</name>
      <address>
        <city>Danderyd Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2008</study_first_submitted>
  <study_first_submitted_qc>February 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2008</study_first_posted>
  <last_update_submitted>February 28, 2008</last_update_submitted>
  <last_update_submitted_qc>February 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Peder M Andersen</name_title>
    <organization>Astion Pharma A/S</organization>
  </responsible_party>
  <keyword>Discoid lupus erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Lupus Erythematosus, Discoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

